Admelog and NovoLog are not the same insulin. They contain two different active molecules: Admelog is insulin lispro, while NovoLog is insulin aspart. Both are rapid-acting insulins used to control blood sugar around mealtimes, and they work on a similar timeline, but they are distinct drugs that cannot be freely substituted for each other at the pharmacy.
Different Molecules, Similar Purpose
Rapid-acting insulins are lab-modified versions of human insulin, tweaked so the body absorbs them faster than regular insulin. Admelog and NovoLog each use a different molecular tweak to achieve that speed. Insulin lispro (Admelog) swaps the position of two amino acids near the end of the insulin molecule. Insulin aspart (NovoLog) replaces one amino acid with a different one entirely. The result is two separate molecules that happen to do a very similar job.
Because the molecules are different, your pharmacist cannot swap one for the other without your prescriber’s approval. This is true even though both land in the same therapeutic category and are often used in the same clinical situations.
How Admelog Relates to Humalog, Not NovoLog
Admelog is specifically a “follow-on” insulin to Humalog, not to NovoLog. Both Admelog and Humalog contain insulin lispro. A follow-on insulin contains the same active ingredient as the original brand but is manufactured by a different company and sold at a lower price. Think of it as similar to a generic, though insulin follow-on products go through a slightly different regulatory pathway than traditional generics.
So if you’re looking for a closer equivalent to NovoLog, that would be another insulin aspart product, not Admelog. And if you’re looking for a lower-cost alternative to Humalog, Admelog fits that role directly.
Onset, Peak, and Duration
Both Admelog and NovoLog start working within about 10 to 15 minutes after injection. NovoLog reaches its peak effect between 1 and 3 hours, with a total duration of 3 to 5 hours. Admelog’s timing profile is nearly identical, as insulin lispro products share a comparable rapid-acting curve. In practice, most people would not notice a difference in how quickly either insulin begins lowering blood sugar or how long the effect lasts.
This overlap in timing is why the two are sometimes discussed as interchangeable options. But “similar timing” and “same drug” are not the same thing. Your body may respond slightly differently to one molecule versus the other, and switching between them is a decision that involves adjusting to a new product under your doctor’s guidance.
Approved Uses and Age Ranges
Admelog is FDA-approved for adults with type 1 or type 2 diabetes and for children ages 3 and older with type 1 diabetes. It is not approved for type 2 diabetes in children. NovoLog carries similar approvals for both type 1 and type 2 diabetes in adults and has pediatric indications as well, though the specific age cutoffs differ slightly depending on the delivery method.
If you’re managing a child’s diabetes, the approved age range for the specific product matters. Your prescriber will factor this in when choosing between the two.
Cost Differences
One of the main reasons people ask whether these two insulins are interchangeable is cost. Based on average retail pricing, Admelog and NovoLog fall in a similar range, though the exact numbers shift depending on your insurance, pharmacy, and any manufacturer discount programs. For reference, retail estimates have placed a 10ml vial of Admelog around $251 and a 10ml vial of NovoLog around $186, with pen packages (five 3ml pens) running roughly $420 for Admelog and $343 for NovoLog.
These figures fluctuate, and what you actually pay depends heavily on your insurance formulary. Some plans favor Admelog with a lower copay because it’s positioned as a follow-on product. Others have preferred pricing for NovoLog. Checking with your insurance or using a pharmacy price comparison tool will give you a more accurate picture of your out-of-pocket cost than list prices alone.
Storage and Handling
Both Admelog and NovoLog follow the same general storage rules that apply to most insulin products. Unopened vials and pens should be refrigerated. Once you start using a vial or pen, it can be kept at room temperature (between 59°F and 86°F) for up to 28 days. After 28 days at room temperature, the insulin should be discarded regardless of how much is left. Neither product should be frozen or exposed to direct heat or sunlight.
Can You Switch Between Them?
Switching from NovoLog to Admelog (or vice versa) is something doctors do regularly, but it requires a new prescription. Your dose may or may not change. Because the two molecules are different, your prescriber will likely want to monitor your blood sugar more closely for a short period after the switch to make sure the new insulin is working as expected. Most people transition without issues, but blood sugar patterns can shift slightly with any insulin change, so extra testing in the first week or two is a reasonable precaution.
If your insurance changes its formulary or you’re looking for a cost savings, switching between rapid-acting insulins is a common and generally straightforward process. Just don’t make the swap on your own by using leftover supplies of one product while prescribed the other.